AACR21: targeting MT1-MMP can act as a guided missile in eradicating osteosarcoma cells

Written by Ryan Gilroy (Future Science Group)

osteosarcoma, cancer cell, tumor

A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center (TX, USA) has demonstrated that an antibody-drug conjugate (ADC) targeting the surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. The study was led by Richard Gorlick, with the findings presented by Yifei Wang (both from The University of Texas MD Anderson Cancer Center) at the virtual American Association for Cancer Research Annual Meeting 2021 (AACR; 9–14 April 2021) . Researchers utilized precision therapy targeting of cell-surface proteins through a fully synthetic novel Bicycle toxin conjugate (BTC),...

To view this content, please register now for access

It's completely free